Øystein Soug
ceo Oncoinvent
Seminars
Wednesday 12th November 2025
Roundtable Discussion: Decentralised VS Centralised Manufacturing: Isotope Dependent Decisions to Ensure Appropriate Manufacturing Strategy
2:00 pm
- Weighing the trade-offs between centralised production hubs for quality control and the logistical challenge of rapid, decentralised distribution to a wider patient base
- Considering how short half-life isotopes like lead-212 drive the need for localised production and affect the balance between decentralisation and centralised control
- Reducing shipping costs, minimising decay-related losses, and enhancing product stability by limiting exposure to radiolysis in decentralised manufacturing models
Wednesday 12th November 2025
Expanding the Scope of Targeted Radiopharmaceuticals
3:30 pm
- Engineering 224Ra labelled microparticles (Radspherin®) to target cancer in body cavities
- Reducing off-target toxicities through targeting by proximity
- Presenting the latest clinical data and development plans for Radspherin® , currently in Phase 2 in ovarian cancer resulting from peritoneal carcinomatosis
